Vident Advisory LLC Boosts Stake in Eli Lilly and Company $LLY

Key Points

• Vident Advisory LLC increased its stake in Eli Lilly by 41.3% in the first quarter, now holding 46,101 shares valued at approximately $38 million.
• Eli Lilly's recent earnings report showed EPS of $6.31, exceeding expectations of $5.59, with a year-over-year revenue increase of 37.6% to $15.56 billion.
• The company declared a quarterly dividend of $1.50, with a corresponding dividend yield of 0.8% and a payout ratio of 39.22%.

Vident Advisory LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 41.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,101 shares of the company's stock after buying an additional 13,484 shares during the period. Vident Advisory LLC's holdings in Eli Lilly and Company were worth $38,078,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Driehaus Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 73.2% in the first quarter. Driehaus Capital Management LLC now owns 1,675 shares of the company's stock worth $1,383,000 after buying an additional 708 shares in the last quarter. Palo Alto Wealth Advisors LLC raised its stake in Eli Lilly and Company by 2.9% during the first quarter. Palo Alto Wealth Advisors LLC now owns 712 shares of the company's stock worth $588,000 after purchasing an additional 20 shares during the period. WPG Advisers LLC purchased a new position in Eli Lilly and Company during the first quarter worth about $335,000. TD Capital Management LLC raised its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after purchasing an additional 31 shares during the period. Finally, Tema Etfs LLC raised its stake in Eli Lilly and Company by 70.0% during the first quarter. Tema Etfs LLC now owns 12,138 shares of the company's stock worth $10,025,000 after purchasing an additional 4,998 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $732.25 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $969.65. The stock has a market cap of $693.05 billion, a PE ratio of 47.86, a P/E/G ratio of 1.02 and a beta of 0.44. The firm has a 50-day simple moving average of $749.30 and a two-hundred day simple moving average of $787.01. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the business earned $3.92 earnings per share. The business's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 22nd. Finally, Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $950.17.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jamere Jackson acquired 200 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the acquisition, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.